Karsten E. Weber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Karsten E. Weber has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Carsten Denkert
Institut für Pathologie, Philipps Universität Marburg und Universitätsklinikum Marburg (UKGM), Marburg, Germany
31 shared publications - Frederik Marmé
Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
30 shared publications - Michael Untch
Klinik für Gynäkologie und Geburtshilfe, Helios Klinikum Berlin-Buch, Berlin, Germany
30 shared publications - Peter Andreas Fasching
Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
30 shared publications - Sibylle Loibl
German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, Germany
30 shared publications - Valentina Nekljudova
German Breast Group, Neu-Isenburg, Germany
30 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data: Figures S1-S6 and Tables S1-S6 from Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
G7 trial design; demographics; tissue types; gene names; displayed data from additional analyses; statistical data
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data: Figures S1-S6 and Tables S1-S6 from Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
G7 trial design; demographics; tissue types; gene names; displayed data from additional analyses; statistical data
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial
Supplementary Figure S2. CAV1 and CAV2 expression in breast cancer.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial
Supplementary Figure S2. CAV1 and CAV2 expression in breast cancer.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial
Supplementary Figure S1. CAV1 and CAV2 before (A, C) and after (B, D) transformation of the continuous expression values.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial
Supplementary Figure S1. CAV1 and CAV2 before (A, C) and after (B, D) transformation of the continuous expression values.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial
Supplementary Figure S3. CAV1 RNA expression is positively correlated with CAV1 protein expression in the TCGA invasive breast carcinoma database.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial
Supplementary Figure S3. CAV1 RNA expression is positively correlated with CAV1 protein expression in the TCGA invasive breast carcinoma database.
- 1 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9  (9) , e2500588
Reply to: Germline and Somatic BRCA1/2 Mutations in Breast Cancer Treatment Strategies
- 1 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9  (9) , e2500588
Reply to: Germline and Somatic BRCA1/2 Mutations in Breast Cancer Treatment Strategies
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Caveolin gene expression predicts clinical outcomes for early-stage HER2-negative breast cancer treated with paclitaxel-based chemotherapy in the GeparSepto trial
Supplementary Figure S2. CAV1 and CAV2 expression in breast cancer.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Caveolin gene expression predicts clinical outcomes for early-stage HER2-negative breast cancer treated with paclitaxel-based chemotherapy in the GeparSepto trial
Supplementary Figure S2. CAV1 and CAV2 expression in breast cancer.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Caveolin gene expression predicts clinical outcomes for early-stage HER2-negative breast cancer treated with paclitaxel-based chemotherapy in the GeparSepto trial
Supplementary Figure S2. CAV1 and CAV2 expression in breast cancer.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Caveolin gene expression predicts clinical outcomes for early-stage HER2-negative breast cancer treated with paclitaxel-based chemotherapy in the GeparSepto trial
Supplementary Figure S2. CAV1 and CAV2 expression in breast cancer.